Featured Scientific Session: "Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory", an accredited continuing medical education (CME) session, with a panel of experts presenting research on OGM's clinical and translational applications.
- Dr. Adam Smith(University of Toronto, Canada; currently at Labcorp, USA) will provide an overview of OGM’s evolution into an essential tool for hematological malignancy research and its role in research of pre- and post-natal constitutional genetic disease.
- Dr. Laila El-Khattabi(Sorbonne University Hospitals and the Brain Institute, Paris, France) will share results from the CHROMAPS project, a multi-institutional European collaboration utilizing OGM to evaluate structural variations and aneuploidies in constitutional and reproductive disorders.
- Dr. Nikhil S. Sahajpal(Greenwood Genetic Center, USA) will present OGM findings from three clinical research cohorts, including neural tube defects (NTDs), undiagnosed rare disorders, and prenatal cases.
- Dr. Rashmi Kanagal-Shamanna(The University of Texas, MD Anderson Cancer Center, USA) will showcase an integrated approach combining OGM and targeted NGS for hematologic malignancies, as well as OGM’s emerging role in quality control for CAR-T cell-based immunotherapies.
- Two additional scientific postersfeaturing results from OGM applications in cancer and in postnatal genetic disorders will be presented at the conference
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2025 with a broad range of scientific content showcasing optical genome mapping (OGM) in key research areas, including hematological malignancies, constitutional genetic disorders, and rare genetic diseases.
ACMG’s Annual Meeting, to be held March 18-22, 2025, in Los Angeles, USA, brings together industry professionals, researchers, and leading experts in clinical genetics to share advancements in genomic technologies.
All scientific posters will be presented in Exhibit Halls DE. Poster presentations and scientific workshop sessions on OGM include:
| Session | Title | Presenter | Presented |
| Scientific Session | Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory | Smith A., El Khatabi L., Sahajpal N., Kanagal-Shamanna R. | March 19, 2025
1:30 PM-3:00 PM PT
Petree Hall C |
| Scientific Session | Introduction to Optical Genome Mapping in Hematologic Malignancies | Dr Adam Smith
(Labcorp, USA) | March 19, 2025
1:30 PM-1:45 PM PT
Petree Hall C |
| Scientific Session | CHROMAPS Prospective Study: Improving Structural Variation Diagnosis in Constitutional Diseases Using OGM | Dr Laila El-Khattabi
(Sorbonne University Hospitals and the Brain Institute, France) | March 19, 2025
1:45 PM-2:05 PM PT
Petree Hall C |
| Scientific Session | Identifying Hidden Structural Variations with OGM in Rare Disorders | Dr Nikhil Sahajpal
(Greenwood Genetic Center, USA) | March 19, 2025
2:05 PM-2:25 PM PT
Petree Hall C |
| Scientific Session | Unleashing OGM for Advancing Precision Therapeutics and Empowering CAR Therapy | Dr Rashmi Kanagal-Shamanna
(MD Anderson Cancer Center, USA) | March 19, 2025
2:25 PM-2:45 PM PT
Petree Hall C |
| Round Table Discussion | Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory | Smith A., El Khatabi L., Sahajpal N., Kanagal-Shamanna R. | March 19, 2025
2:45 PM-3:00 PM PT
Petree Hall C |
| Poster Number | Title | Authors | Presented |
| P733 | Improved Algorithms for Optical Genome Mapping Workflows in Constitutional Disease and Oncology Applications | Pang A. | March 20, 2025
10:30 AM-11:30 AM PT Exhibit Hall
|
| P782 | A Complex Structural Rearrangement Resulting in Recurrent SCN1A Deletion Identified by Optical Genome Mapping | Butler K. | March 21, 2025
10:30 AM- 11:30 AM PT
Exhibit Hall |
Erik Holmlin, PhD, president and chief executive officer of Bionano, added, “Our presence at ACMG 2025 reflects the growing impact of optical genome mapping in clinical research. Although we are operating with a smaller footprint, in order to reduce expenses, the OGM community has assembled an outstanding lineup of presentations from individuals at leading institutions, that showcase how OGM continues to drive research advancements in hematological malignancies, rare genetic disorders, and constitutional genomics. We believe the growth in data and content about OGM’s enhanced utility in the cytogeneticist’s toolbox reflects the acceptance of OGM for routine use. We are eager to hear from many well-known experts in the field, including Dr Adam Smith who is currently at Labcorp."
More details on Bionano’s conference events can be found https://bionano.com/events/
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “may,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: OGM’s utility for applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s 2025 Annual Meeting; the utility of OGM for cytogeneticists the utility and adoption of OGM for routine use; and the growth and adoption of OGM generally. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including bank failures, inflation, supply chain disruptions, and regional or global pandemics, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM to prove useful in areas including applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s 2025 Annual Meeting; the failure of OGM to prove useful to cytogeneticists; the failure of OGM to be accepted for routine use; the failure of laboratories to adopt OGM generally; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ACMG’s 2025 Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ACMG’s 2025 Annual Meeting; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to consummate any strategic alternatives; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
